Motilent

Motilent is a medical imaging software company focused on the gastrointestinal tract, serving researchers, clinicians, and life sciences organisations working across digestive diseases including Crohn's disease, inflammatory bowel disease (IBD), constipation, gastroparesis, and IBS. Founded by Alex Menys PhD, the company originated from academic research and was established to translate advanced gastrointestinal imaging technologies — including MRI, ultrasound, and capsule endoscopy — into practical clinical and research tools. Motilent's products support clinical practice, academic research, and pharmaceutical clinical trials, with 15 of the top 20 pharma companies using its Entrolytics platform and 11 Phase 3 trials conducted on the platform.

The company places emphasis on real-world evidence as a guiding principle for deploying emerging technologies safely and effectively. Its platform and tools are designed to bridge the gap between advanced imaging science and everyday clinical and research workflows, with a particular focus on non-invasive, objective assessment of gastrointestinal function.

Core Products

• Entrolytics: A secure, end-to-end medical imaging platform purpose-built for gastrointestinal data. It supports the full workflow — ingestion, storage, viewing, quantification, and communication — in a single environment. Entrolytics is designed for use in clinical practice, research, and clinical trials, combining multimodality data with clinical insight. It is described by users as functioning similarly to a PACS system but optimised for gastrointestinal and IBD imaging, with support for multi-rater scoring, mark-up, and auditable research workflows. The platform is FDA listed for image reading and hosts over 4.8 million images across 165 projects with 240 active users.
• GIQuant: A software solution that analyses cine (dynamic) MRI sequences of the small bowel and converts them into a quantitative motility score. GIQuant provides a validated, objective measure of bowel movement to quantify Crohn's disease activity, enabling treatment response tracking over time. It is CE marked (Class IIa) and FDA Cleared (Class II) for use in both adults and children.
• Bridge: A secure solution for capturing, storing, and sharing intestinal ultrasound (IUS) data. Bridge connects directly to ultrasound machines, automatically de-identifies patient data, and integrates with Entrolytics for compliant and reliable workflows. It is suited for clinical trials, routine clinical practice, and education.
• vEUA (Virtual Examination Under Anaesthetic): A 3D modelling tool for pelvic and perineal anatomy. vEUA generates anatomically representative models of the sphincters, levator plate, and fistula tracts from MRI data in under two minutes. It is intended to assist surgeons and radiologists in procedure planning, colleague communication, and patient-facing visualisation of complex disease.

Clinical and Research Applications

• Assessment of treatment response in inflammatory bowel disease, including Crohn's disease activity quantification via small bowel motility scoring.
• Support for Phase 3 pharmaceutical clinical trials involving gastrointestinal imaging endpoints.
• Multi-centre clinical research with auditable, traceable imaging data and measurements.
• Research into gastrointestinal conditions including constipation, gastroparesis, and IBS.
• Stomach and colon motility analysis using tools such as STMM, which measures the size and coordination of contractions non-invasively.
• Interventional studies on small bowel motility using MRI, with access to both standard and advanced analysis tools.

Compliance, Regulatory Status, and Notable Customers

• GIQuant holds CE marking (Class IIa) and FDA Clearance (Class II) for use in adults and children.
• Entrolytics is FDA listed for image reading.
• 15 of the top 20 global pharmaceutical companies use the Entrolytics platform.
• The platform has supported 11 Phase 3 clinical trials.
• Users and collaborators include institutions such as University College London, Cincinnati Children's Hospital, Aalborg University Hospital (Denmark), University of Nottingham, and University College London Hospitals (UCLH).
• Bridge is designed for compliant data capture and sharing, with automatic patient data de-identification built into the workflow.

Integrations and Deployment

• Entrolytics is a web-based platform, enabling access without dependency on local PACS infrastructure or proprietary software installations.
• Bridge connects directly to ultrasound machines and links to Entrolytics for an integrated intestinal ultrasound data workflow.
• The platform supports multimodality data, accommodating MRI, ultrasound, and endoscopy imaging within a single environment.

Motilent collaborates with international academic and clinical partners and is actively engaged in research across a broad range of gastrointestinal conditions, with a stated commitment to advancing non-invasive imaging technologies and making objective, quantitative gastrointestinal assessment accessible in both research and routine clinical settings.